Table 1.
Pharmacokinetic parameters of DWP16001, dapagliflozin, and ipragliflozin after a single oral administrations of DWP16001, dapagliflozin, and ipragliflozin at a dose of 1 mg/kg in ICR mice, respectively.
| Parameters | DWP16001 | Dapagliflozin | Ipragliflozin | |
|---|---|---|---|---|
| Plasma | Cmax (ng/mL) | 371.4 ± 108.6 | 274.8 ± 143.6 | 409.6 ± 59.1 |
| Tmax (h) | 0.7 ± 0.3 | 0.5 ± 0.0 | 0.6 ± 0.2 | |
| AUC72h (μg∙h/mL) | 1.69 ± 0.34 | 0.48 ± 0.18 * | 1.96 ± 0.41 | |
| AUC∞ (μg∙h/mL) | 1.73 ± 0.34 | 0.55 ± 143.8 * | 1.97 ± 0.41 | |
| t1/2 (h) | 3.8 ± 1.4 | 2.1 ± 0.2 * | 3.1 ± 0.5 | |
| Kidney | AUC72h (μg∙h/g tissue) | 139.2 ± 5.19 | 26.30 ± 3.34 * | 73.65 ± 7.05 * |
| AUC ratio | 85.0 ± 16.1 | 64.6 ± 31.8 | 38.4 ± 5.3 * | |
| t1/2 (h) | 125.5 ± 80.4 | 24.9 ± 5.4 * | 24.3 ± 5.7 * |
Area under curve (AUC) ratio: Ratios of Kidney AUC to plasma AUC; Data expressed as mean ± SD from five mice; *: p < 0.05, compared with DWP16001 group.